RPG Life Sciences – Investor Presentation Summary
Key Operational Highlights
- Salesforce productivity consistently improving (currently >6.5 lakhs)
- Manufacturing facilities: 4 (Formulation in Ankleshwar, Gujarat; API in Navi Mumbai, Maharashtra)
- Employees: 1445+
- Markets presence: 50+
- Therapies represented: 9 by High Equity Brands
- Leader in Immunosuppressants
Key drivers of operational performance: Focus on chronic & specialty therapies, digital initiatives in manufacturing and quality, scalable capabilities across formulation and API units.
Segment-wise Performance
Domestic Formulations (DF)
- Contributed to total sales (percentage not specified)
- Q1 FY27 Performance: Not specified with exact figures
- Growth: Not specified with exact percentage
International Formulations (IF)
- Contributed 18.0% to total sales in Q1 FY27
- Q1 FY26: ₹32.5 crore
- Q1 FY27: ₹35.0 crore
- Growth: +7.7% YoY
API
- Contributed 13.7% to total sales in Q1 FY27
- Q1 FY26: ₹19.6 crore
- Q1 FY27: ₹26.6 crore
- Growth: +35.6% YoY
Explanation of significant changes in segment performance: API growth was impacted due to fire incident in one of the manufacturing blocks, yet showed strong recovery. International Formulations growth driven by focus on long-term business development activities including adding new products, customers and markets.
Financial Highlights
Revenue: Not specified with exact consolidated figure (segments show ₹35.0 cr IF + ₹26.6 cr API + DF unknown)
EBITDA: Not specified
PAT: Not specified
EPS: Not specified
Margins: Not specified
YoY/QoQ comparison: Consolidated revenue up by 15.8% YoY
Drivers of financial performance: Improved profitability, growth across business segments
Comparison to market estimates: Not available
Key Risks: Fire incident in API manufacturing block impacting growth
Geographical Revenue Split
Domestic vs Export/Regional Revenue:
- Domestic: Not specified
- Export: Not specified
Regional Breakdown: International presence across Canada, UK, Germany, France, Australia, SE Asia, Africa, LATAM, China, South Korea, Iran, Bangladesh, Egypt, and more
Balance Sheet Snapshot
Net Debt/Equity: Not specified
Reserves: Not specified
Current Assets/Liabilities: Not specified
Working Capital/Leverage Metrics: Not specified
Financial Health Insights: Robust capital structure, strong debt servicing indicators, healthy cash flows, strong balance sheet, no debt-funded capital expenditure
Capex & Cash Flow Health
Capital Expenditure: ₹185+ crores capex infused since FY22
Free Cash Flow: Not specified
Operating Cash Flow: Not specified
Net Debt Movement: Not specified
Investment Rationale: Building modern plant with EU, TGA, PMDA approvals, improving manufacturing productivity
Strategic & R&D Initiatives
Investments in Innovation: Digital initiatives in manufacturing and quality (Digital Retina Scanner, Intelligent Chilling Plant Manager, IOT based AHU monitoring system, Power Management System, e-QMS, e-DMS, e-LMS)
Expected impact on growth: Improving efficiency & compliance, reducing costs and growing topline
Strategic Rationale: Portfolio development and mega-brands building, growing API business, expanding global presence
Industry Trends & Business Environment
Macro/Industry Trends: Not specified
Impact on Company: Not specified
Management Commentary & Growth Outlook
Strategic Outlook: Driving a more purpose-led and performance-oriented organization with stronger alignment across teams
FY Guidance: Project to grow immunosuppressant portfolio to 200+ crores; grow Naprosyn to 100+ crores brand
Market Share Targets: Not available
Risks and Opportunities: Fire incident in manufacturing block; evaluation of multiple M&A proposals underway for growth synergy
Additional Headings
ESG Updates
- Embedding cost discipline and ESG-led practices to drive long-term sustainable operations
Digital Transformation
- Multiple digital initiatives designed to streamline front-end and backend operations
- Focus on improving efficiency & compliance, reducing costs and growing topline
Awards & Recognition
- Awarded "Top Nephrology Company-2026" for strong patient care in kidney care space
- Awarded for "Best Use of AI in Sales Force Effectiveness"
- Awarded for "Excellence in Breakthrough Pharmaceutical Innovations" for sales force effectiveness measures
Credit Rating Update
- ICRA reaffirmed long-term rating at A+ with stable outlook (June 2026)
- Short-term rating reaffirmed at A1
- Factors: Robust capital structure, strong debt servicing indicators, healthy cash flows, strong balance sheet, no debt-funded capex, steady growth in top-line, improving operating margins